These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 20839258)

  • 1. Differences in incidence and co-occurrence of vaccine and nonvaccine human papillomavirus types in Finnish population before human papillomavirus mass vaccination suggest competitive advantage for HPV33.
    Merikukka M; Kaasila M; Namujju PB; Palmroth J; Kirnbauer R; Paavonen J; Surcel HM; Lehtinen M
    Int J Cancer; 2011 Mar; 128(5):1114-9. PubMed ID: 20839258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination.
    Palmroth J; Merikukka M; Paavonen J; Apter D; Eriksson T; Natunen K; Dubin G; Lehtinen M
    Int J Cancer; 2012 Dec; 131(12):2832-8. PubMed ID: 22492244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of being seropositive for multiple human papillomavirus types among Finnish and Ugandan women.
    Namujju PB; Surcel HM; Kirnbauer R; Kaasila M; Banura C; Byaruhanga R; Muwanga M; Mbidde EK; Koskela P; Lehtinen M
    Scand J Infect Dis; 2010 Jul; 42(6-7):522-6. PubMed ID: 20180681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population dynamics of serologically identified coinfections with human papillomavirus types 11, 16, 18 and 31 in fertile-aged Finnish women.
    Kaasila M; Koskela P; Kirnbauer R; Pukkala E; Surcel HM; Lehtinen M
    Int J Cancer; 2009 Nov; 125(9):2166-72. PubMed ID: 19585500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of human papillomavirus type replacement among young pregnant Finnish females before and after a community-randomised HPV vaccination trial with moderate coverage.
    Gray P; Kann H; Pimenoff VN; Adhikari I; Eriksson T; Surcel HM; Vänskä S; Dillner J; Faust H; Lehtinen M
    Int J Cancer; 2020 Dec; 147(12):3511-3522. PubMed ID: 32574384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.
    Brown DR; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Koutsky LA; Tay EH; Garcia P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Joura EA; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; Sings HL; James M; Hesley TM; Barr E
    J Infect Dis; 2009 Apr; 199(7):926-35. PubMed ID: 19236279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Annual disease burden due to human papillomavirus 16 and 18 infections in Finland.
    Syrjänen KJ
    Scand J Infect Dis Suppl; 2009; 108():2-32. PubMed ID: 19939209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age and geographic variability of human papillomavirus high-risk genotype distribution in a large unvaccinated population and of vaccination impact on HPV prevalence.
    Carozzi F; De Marco L; Gillio-Tos A; Del Mistro A; Girlando S; Baboci L; Trevisan M; Burroni E; Grasso S; Giorgi Rossi P; Ronco G;
    J Clin Virol; 2014 Jul; 60(3):257-63. PubMed ID: 24815381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
    Barzon L; Squarzon L; Masiero S; Pacenti M; Marcati G; Mantelli B; Gabrielli L; Pascucci MG; Lazzarotto T; Caputo A; Palù G
    Vaccine; 2014 Sep; 32(41):5357-62. PubMed ID: 25045814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy.
    Lehtinen M; Idänpään-Heikkilä I; Lunnas T; Palmroth J; Barr E; Cacciatore R; Isaksson R; Kekki M; Koskela P; Kosunen E; Kuortti M; Lahti L; Liljamo T; Luostarinen T; Apter D; Pukkala E; Paavonen J
    Int J STD AIDS; 2006 Apr; 17(4):237-46. PubMed ID: 16595046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measuring serum antibody to human papillomavirus following infection or vaccination.
    Frazer IH
    Gynecol Oncol; 2010 Jun; 118(1 Suppl):S8-11. PubMed ID: 20494221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine.
    Giuliano AR; Lazcano-Ponce E; Villa L; Nolan T; Marchant C; Radley D; Golm G; McCarroll K; Yu J; Esser MT; Vuocolo SC; Barr E
    J Infect Dis; 2007 Oct; 196(8):1153-62. PubMed ID: 17955433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Distribution of serum antibodies against human papillomavirus 16 and 18 among high-risk women to cervical cancer].
    Fei M; Li J; Du J; You J; Zhang S; He W; Kang L; Zhao F; Qiao Y; Si Y; Fan X; Chen W
    Zhonghua Liu Xing Bing Xue Za Zhi; 2014 May; 35(5):514-8. PubMed ID: 25059358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine-related HPV genotypes in women with and without cervical cancer in Mozambique: burden and potential for prevention.
    Castellsagué X; Klaustermeier J; Carrilho C; Albero G; Sacarlal J; Quint W; Kleter B; Lloveras B; Ismail MR; de Sanjosé S; Bosch FX; Alonso P; Menéndez C
    Int J Cancer; 2008 Apr; 122(8):1901-4. PubMed ID: 18076064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses.
    Barnabas RV; Laukkanen P; Koskela P; Kontula O; Lehtinen M; Garnett GP
    PLoS Med; 2006 May; 3(5):e138. PubMed ID: 16573364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human papillomavirus typing in reporting of condyloma.
    Sturegård E; Johansson H; Ekström J; Hansson BG; Johnsson A; Gustafsson E; Dillner J; Forslund O
    Sex Transm Dis; 2013 Feb; 40(2):123-9. PubMed ID: 23324975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004.
    Markowitz LE; Sternberg M; Dunne EF; McQuillan G; Unger ER
    J Infect Dis; 2009 Oct; 200(7):1059-67. PubMed ID: 19719390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types.
    Huber B; Schellenbacher C; Jindra C; Fink D; Shafti-Keramat S; Kirnbauer R
    PLoS One; 2015; 10(3):e0120152. PubMed ID: 25790098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine.
    Ault KA; Giuliano AR; Edwards RP; Tamms G; Kim LL; Smith JF; Jansen KU; Allende M; Taddeo FJ; Skulsky D; Barr E
    Vaccine; 2004 Aug; 22(23-24):3004-7. PubMed ID: 15297048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
    Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
    Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.